Haemoglobin changes and disease activity in Japanese patients with rheumatoid arthritis treated with sarilumab
Yoshiya Tanaka(University of Occupational and Environmental Health Japan), Hideto Kameda(Toho University), Hubert van Hoogstraten(Sanofi (United States)), Amy Praestgaard(Sanofi (France)), Toshiya Takahashi(Tohoku University), Naoto Kato(Jichi Medical University)
Cited by 2
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
|Annals of the Rheumatic Diseases|2007|413